11,550.00
+100.00
+(0.87%)
At close: 3:30:29 PM GMT+9
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Jong-Won Choi | Joint Chief Executive Officer | -- | -- | 1967 |
| Ho-Suk Chon | Joint Chief Executive Officer | -- | -- | 1958 |
| Yeong-Jin Kim | President | -- | -- | 1970 |
| Seok-Yong Choi | Chief Operating Officer and Senior Managing Director | -- | -- | 1962 |
Hyundai Bioscience Co., Ltd.
150, Bugahyeon-ro
3rd Floor Seodaemun-gu
Seoul, 03759
South Korea
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.
Corporate Governance
Hyundai Bioscience Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 14, 2025 at 10:59 AM UTC - May 19, 2025 at 12:00 PM UTC
Hyundai Bioscience Co., Ltd. Earnings Date
Recent Events
Recent Events Information Not Available